Request for Exclusive Sample on Glucagon-like Peptide 1 (GLP-1) Analogues Market: Evolution of GLP-1 Therapy: From Ozempic to Triple Agonists The GLP-1 race is moving in waves
Background Hims 2025 revenue guidance has raised concerns that its become over-reliant on compounded semaglutide Critics question the sustainability of this business model now that the FDA has ended the semaglutide shortage On February 24, Hims & Hers management released aggressive full year guidance for 2025 that assumed $2.3-2.4 billion in revenue, an increase of nearly 60 percent compared to the prior year
2.3 Yurpeak: Ciplas Tirzepatide Franchise In December 2025, Cipla announced the launch of Yurpeak, a once-weekly tirzepatide injection for obesity and type 2 diabetes, under a partnership where: Lilly manufactures and supplies tirzepatide (same price as Mounjaro)
Particularly, the ability to reduce weight has increased their use among patients who are obese but do not have diabetes
By type of molecule, the biologics segment is expected to report substantial growth during the forecast period
Like the injection, they'll be prescription-only once available in the UK
.png.jpg)